Understanding Carvykti™

Carvykti™ (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of adult patients with relapsed or refractory myeloma after four or more prior lines of therapy. Carvykti uses a patient’s own T cells, which are collected and genetically modified, then infused back into the patient. Carvykti works by recognizing and binding to BCMA, a protein on myeloma cells, leading to the destruction of BCMA-expressing cells, thereby eliminating the myeloma cells.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.